Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Evaxion A/S changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 9 | 9 | 0 |
| Shares | 258.2K | 161.3K | −96.9K (−37.5%) |
| Value | $291.4K | $209.8K | −$81.6K (−28.0%) |
New holders (2)
Institutions that held Evaxion A/S at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| JPMorgan Chase & Co | 29,154 | $37.9K | 0.00% |
| Rhumbline Advisers | 2,109 | $2.74K | 0.00% |
Sold out (2)
Institutions that held Evaxion A/S at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Millennium Management LLC | 29,141 | $33.0K |
| Two Sigma Securities, LLC | 10,443 | $11.8K |